Wilms Patrick, Schröder Jan, Scheit Lorenz, Reer Rüdiger
Institut für Bewegungswissenschaft, Sport- und Bewegungsmedizin, Universität Hamburg, Turmweg 2, 20148, Hamburg, Deutschland.
Abteilung I - Innere Medizin, Bundeswehrkrankenhaus Hamburg, Lesserstr. 180, 22049, Hamburg, Deutschland.
Orthopadie (Heidelb). 2024 Sep;53(9):668-676. doi: 10.1007/s00132-024-04541-3. Epub 2024 Aug 22.
Tendinopathies are diseases that often entail long-term treatment consisting of analgesics, physiotherapy, orthotics, and sparing. The aim of this study was to investigate the effect of a single application of a high-energy PEMF (pulsed electromagnetic field) on pain perception and blood born inflammation parameters.
34 patients were randomly assigned to a verum group (10 min PEMF, 0,78 T) or a placebo group (10 min sham condition). Prior to and up to one week after the patient blinded treatment (t1-t5), local pain state was assessed by means of algometry as pain pressure threshold (PPT). Accordingly, heat-shock protein 70 (HSP70) levels were analysed. Statistical analyses included 2‑way ANOVA (2 × 5). The clinical trial was registered (DRKS00031321).
After randomization and drop-out (verum n = 17, placebo n = 13) baseline-analyses did not reveal significant between-group differences for PPT (p = 0,096), for HSP70 (p = 0,524), or any other sample characteristics (p > 0,05). Pain reduction during one week of observation showed to be significantly higher (p = 0,045, η = 0,013) for the PEMF group (PPT: +83 bis +139%) compared to the placebo group (PPT: +10 bis +36%). There were no HSP70 associated effects.
A single bout of high energy PEMF led to an immediate pain relief in tendinopathy patients lasting at least for one week, but the hypothesized underlying HSP70 associated inflammatory pathway could not be confirmed.
肌腱病通常需要长期治疗,包括使用镇痛药、物理治疗、矫形器和减少活动。本研究的目的是调查单次应用高能脉冲电磁场(PEMF)对疼痛感知和血液炎症参数的影响。
34例患者被随机分为治疗组(10分钟PEMF,0.78T)或安慰剂组(10分钟假刺激条件)。在患者接受盲法治疗前及治疗后一周内(t1 - t5),通过压力痛觉测定法评估局部疼痛状态,即疼痛压力阈值(PPT)。相应地,分析热休克蛋白70(HSP70)水平。统计分析包括双向方差分析(2×5)。该临床试验已注册(DRKS00031321)。
随机分组和剔除后(治疗组n = 17,安慰剂组n = 13),基线分析显示两组在PPT(p = 0.096)、HSP70(p = 0.524)或任何其他样本特征方面无显著组间差异(p>0.05)。在一周的观察期内,与安慰剂组(PPT:+10至+36%)相比,PEMF组的疼痛减轻显著更高(p = 0.045,η = 0.013)(PPT:+83至+139%)。未发现与HSP70相关的效应。
单次应用高能PEMF可使肌腱病患者立即缓解疼痛,且至少持续一周,但未能证实假设的潜在HSP70相关炎症途径。